Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study

Authors

Lihua E Budde, City of Hope National Medical Center
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al

Journal

Journal of Clinical Oncology

Publication Date

2-10-2022

Volume

40

Issue

5

First Page

481

Last Page

491

Document Type

Open Access Publication

DOI

10.1200/JCO.21.00931

Rights and Permissions

Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931 Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Budde, Lihua E; Bartlett, Nancy L; and et al, "Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study." Journal of Clinical Oncology. 40, 5. 481 - 491. (2022).
https://digitalcommons.wustl.edu/oa_4/331